מונוקורד 40 ישראל - עברית - Ministry of Health

מונוקורד 40

dexcel ltd, israel - isosorbide mononitrate - טבליה - isosorbide mononitrate 40 mg - isosorbide mononitrate - isosorbide mononitrate - for the treatment of angina pectoris and prevention of anginal attacks, treatment of congestive heart failure.

מונוקורד 20 ישראל - עברית - Ministry of Health

מונוקורד 20

dexcel ltd, israel - isosorbide mononitrate - טבליה - isosorbide mononitrate 20 mg - isosorbide mononitrate - isosorbide mononitrate - for the treatment of angina pectoris and prevention of anginal attacks. treatment of congestive heart failure.

אולטיברו בריזהלר 11050 מקג ישראל - עברית - Ministry of Health

אולטיברו בריזהלר 11050 מקג

novartis israel ltd - glycopyrronium as bromide; indacaterol as maleate - אבקה לשאיפה בקפסולות קשיחות - indacaterol as maleate 110 mcg; glycopyrronium as bromide 50 mcg - indacaterol

מונוקורד 50  SR ישראל - עברית - Ministry of Health

מונוקורד 50 sr

dexcel ltd, israel - isosorbide mononitrate - טבליות בשחרור איטי - isosorbide mononitrate 50 mg - isosorbide mononitrate

ויאגרה 25 מג ישראל - עברית - Ministry of Health

ויאגרה 25 מג

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 25 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

ויאגרה 50 מג ישראל - עברית - Ministry of Health

ויאגרה 50 מג

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 50 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

ויאגרה 100 מג ישראל - עברית - Ministry of Health

ויאגרה 100 מג

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 100 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

אוויפלרה ישראל - עברית - Ministry of Health

אוויפלרה

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

אוויפלרה ישראל - עברית - Ministry of Health

אוויפלרה

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme